| Date | Title | Description |
| 06.03.2026 | Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management | HANGZHOU, China, March 6, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced toda... |
| 27.02.2026 | Global Pharma Giants Bet Big on China's Weight-Loss Innovations | Pfizer significantly invests in China's surging weight-loss drug market. A landmark partnership with Sciwind Biosciences grants Pfizer exclusive commercialization rights for Ecnoglutide, a cutting-edge GLP-1 receptor agonist, in mainland Ch... |
| 25.02.2026 | Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs | (Yicai) Feb. 25 -- Global pharmaceutical heavyweights, including the likes of Pfizer and AstraZeneca, are shelling out huge sums to secure the licensing rights to Chinese weight-loss drugs, as a fierce scramble for next-generation obesity t... |
| 24.02.2026 | Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China | HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a... |
| 03.02.2026 | China Approves Groundbreaking Type 2 Diabetes Treatment: Ecnoglutide Marks Global First | Sciwind Biosciences achieved a major milestone. China's NMPA approved ecnoglutide for Type 2 Diabetes. This therapy is the world's first approved cAMP-biased GLP-1 receptor agonist. It provides powerful glycemic control, substantial weight ... |
| 30.01.2026 | Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes | HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that Ch... |
| 28.01.2026 | Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications | HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2... |
| 25.07.2025 | Health insurer Centene reports surprise quarterly loss | Health insurer Centene reports surprise quarterly loss
By ReutersJuly 25, 202510:08 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A sign for Wellcare, part of the Centene Corporation, is seen ... |
| 25.07.2025 | Exclusive: China's Sciwind is in talks to license weight-loss drug in US, CEO says | Exclusive: China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew SilverJuly 25, 20257:45 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A Sciwind sign is displayed o... |
| 10.01.2025 | Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio | HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaborati... |
| 08.10.2024 | Sciwind Biosciences Announces Oral Presentation on Oral GLP-2 Research Progress at the 32nd United European Gastroenterology Week (UEG Week 2024) | BEIJING and HANGZHOU, China, Oct. 8, 2024 /PRNewswire/ -- The 32nd United European Gastroenterology Week (UEG Week 2024) will take place in Vienna, Austria, from October 12 to 15, 2024. UEG Week is the largest gastroenterology conference in... |
| 06.09.2024 | Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024) | HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announc... |
| 22.06.2024 | Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conf... | A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnogl... |
| 07.05.2024 | Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea | HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean ... |
| 07.05.2024 | Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea | HANGZHOU, China and SEOUL, South Korea, May 7, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean ... |
| 24.01.2024 | Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide | Oral ecnoglutide was safe and well tolerated with gastrointestinal side effects as the most commonly reported adverse events
Study participants receiving up to 30 mg oral ecnoglutide once-daily for 6 weeks achieved a mean body weight reduct... |
| 03.01.2024 | Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in C... | Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo
In the 1.2 mg ecnoglutide cohort, 76.1% of participants... |
| 12.07.2023 | Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism | HANGZHOU, China and SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announc... |
| 24.06.2023 | Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference | Results from three clinical studies show ecnoglutide to be safe and well-tolerated, and demonstrate robust therapeutic effects in overweight/obese and type 2 diabetes patients
On-going Phase 3 clinical trials in Chinese patients with type 2... |
| 31.01.2023 | Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China | HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced toda... |
| 28.10.2022 | Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity | - Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks
- 88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of ≥5% and ≥10%, respectively
- XW003 ... |
| 10.10.2022 | Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes | HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced toda... |
| 27.09.2022 | Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics | The partnership combines Sciwind's expertise in disease biology and clinical development capabilities with SynerK's proprietary conjugate-based siRNA delivery technology and expertise in developing RNAi therapeutics
SAN FRANCISCO, Calif. an... |
| 09.08.2022 | Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China | Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14 weeks, respectively
Up to 72.4% of participants achieved weight loss of at least 5% at week 14
XW003 was safe and well tolerated with gastrointe... |
| 03.08.2022 | Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China | - Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose
- Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved HbA1c ≤ 6.5% at the end of the 20-week treatment
- XW003 was safe and well tolerated with gastrointe... |
| 09.06.2022 | Sciwind Biosciences to present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022 | HANGZHOU, China and SAN FRANCISCO, June 9, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announce... |
| 14.04.2022 | Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide) | HANGZHOU, China and SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announc... |
| 18.01.2022 | Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity | HANGZHOU, China and SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announce... |
| 09.12.2021 | Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients | HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced... |
| 30.11.2021 | Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease | HANGZHOU, China and SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced toda... |
| 13.10.2021 | Sciwind Biosciences Raised $70M in Series C Funding | Sciwind Biosciences, a Hangzhou, China and San Francisco CA-based clinical-stage biopharmaceutical company, raised $70M in Series C funding.
The round was led by Financing Supported by IDG Capital, Loyal Valley Capital and LYFE Capital.
Led... |
| 12.10.2021 | Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline | HANGZHOU, China and SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announc... |
| 19.02.2021 | Sciwind Biosciences Raises US$37M in Series B Financing | Hangzhou Sciwind Biosciences Co., Ltd., a Hangzhou, China-based clinical-stage biopharmaceutical company focusing on research and development of innovative biologics, closed a US$37M series B financing.
The round was led by LYFE Capital and... |
| 15.02.2019 | Legend leads $29m round in China’s Sciwind Biosciences | Premium
Beijing-headquartered venture capital firm Legend Capital has led the RMB200 million ($29 million) Series A funding of Chinese drug developer Sciwind Biosciences, which is focused on treating metabolic disorders, China Money Network... |
